• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Should You Buy AstraZeneca After Its Positive Vaccine News?

Here's my view on this space and where the money is to be made.
By STEPHEN GUILFOYLE
Mar 22, 2021 | 10:45 AM EDT
Stocks quotes in this article: AZN, MRNA, PFE, BNTX, JNJ

Given the news over the past few weeks, the news has to be seen as complex. First, Monday morning starts out with good news. AstraZeneca (AZN) announced trial data from its U.S. study for the firm's Covid-19 vaccine (that had already been authorized for use in many nations) indicates a 79% efficacy rate for the prevention of symptomatic Covid, as well as 100% effectiveness in preventing death or severe disease.

The firm says that it has 13 million doses in the U.S. ready to roll, and is expected to file with the FDA in coming weeks for "Emergency Use Authorization", and if granted would become the fourth vaccine in the U.S. arsenal that already includes Messenger RNA vaccines manufactured by Moderna (MRNA) and a joint Pfizer (PFE) /BioNTech (BNTX) venture, as well as the adenovirus-based vaccine manufactured and distributed by Johnson & Johnson (JNJ) . The AZN candidate is also adenovirus-based derived from a chimpanzee coronavirus deemed very similar to the SARS-CoV-2 virus that causes Covid.

There is belief that as the U.S. is way ahead of the rest of the developed world in vaccination rates and that such campaigns in many less developed areas are yet to begin, that the U.S. could use this AstraZeneca vaccine to support global distribution rather than rollout broadly for domestic use.

Problems?

There are questions. The U.S. study, or at least what we know about it involved 32,449 individuals, and found the vaccine to be well-tolerated. The group was studied for what are known as "thrombotic events" or more plainly... blood clots in the brain. The board monitoring the study found no increased risk for such events among the 21,583 individuals who did actually receive at least one dose of this vaccine.

As we know, across Europe where the AstraZeneca vaccine has been a driver of the continent's vaccination program, a number of countries halted use of the AZN vaccine despite vaccination rates across the EU of just 2% to 3%, and in some countries new infection rates that are once again on the rise. There were at least 30 cases of CVST or Cerebral Venous Sinus Thrombosis across Europe in recently vaccinated individuals who tended to be younger females.

On the one hand, there are studies that show no statistically significant increase in blood clots for those vaccinated than from those not vaccinated. On the other hand two separate groups of medical researchers, one in Germany and one in Norway as reported in the Wall Street Journal last Friday, said that they had identified a mechanism that could lead this vaccine to cause these blood clots in rare instances. One slice of positivity would be that even if these researchers are correct, that the condition would be treatable.

Even as parts of France and Italy went back into social and economic lockdown last week. Germany, France, and Italy resumed the use of this vaccine, while the Scandinavian nations of Norway, Sweden, and Denmark seem reluctant to do so.

 

Readers will easily see that AZN has been in a state of gradual price erosion since spoiling last summer. Interesting the $46 level also happens to be a near perfect 61.8% Fibonacci retracement of the stock's move from the lows of March 2020 through that summer spike, and that level worked to precision for those seeking support earlier this month.

Would I buy this name right now? No. That's because I already have a pharmaceutical in my inventory that really does not perform all that well, but pays a nice dividend. That would be Pfizer. Over the past six months, PFE has gained a rather paltry 4%, but that stock does pay 4.4%. AZN pays a nice 3.9%, but the stock is down 9% over those same six months.

The money, I think, and this is just an opinion, to be made in this space is in the biotechs that worked on and (seemingly) perfected Messenger RNA technology. That's Moderna and that's BioNTech. This may be a stretch, but it's just what I am thinking but Messenger RNA technology is not just how we defeat Covid tomorrow, but how we defeat all coronaviruses the day after that, and maybe one day... disease. Period. Pfizer and AstraZeneca are fine for a dividend book. The biotechs that craft this until now experimental technology, despite incredibly volatile in the day to day pricing, are where I think I want to invest. That said, it's not like I am selling my Pfizer.

P.S. - If you really want to buy AZN, I think you get another crack at $46. This battle at the 50-day simple moving average is short-term crucial.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long PFE, MRNA equity.

TAGS: Drug Approvals | Investing | Markets | Stocks | Technical Analysis | Trading | Biotechnology | Pharmaceuticals | Coronavirus

More from Investing

General Mills Could Struggle to Make New Highs

Bruce Kamich
Mar 23, 2023 1:45 PM EDT

The volume indicators do not confirm recent gains.

Floating-Rate Debt Helps Lift This ETF

Mark Abssy
Mar 23, 2023 12:42 PM EDT

The American Century Multisector Floating Income exchange-traded fund stands out in this economy.

Ford Shares Could Start to Go Downhill

Bruce Kamich
Mar 23, 2023 12:10 PM EDT

Let's see what the charts look like.

Block Stock Sinks Like a Rock After Hindenburg Report

Bruce Kamich
Mar 23, 2023 11:00 AM EDT

Here's what traders should do now.

There's a Lot to Chew on Here, But Chewy Stock Is a Work in Progress

Stephen Guilfoyle
Mar 23, 2023 10:45 AM EDT

At a minimum it belongs on a watch list.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 05:00 PM EDT CHRIS VERSACE

    AAP Podcast on the Fed Decision!

    Listen here!
  • 02:38 PM EDT REAL MONEY

    Fed Hikes Rates 25 Basis Points

    Here's what stood out in the statement.
  • 10:28 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    There are exceptions to conventional trading wisdo...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login